Overview

Continuation of Antiarrhythmics Following Ventricular Tachycardia Catheter Ablation

Status:
Recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
The investigators aim to study if patients that undergo catheter ablation for ventricular tachycardia benefit from continuation of Vaughan-Williams class III antiarrhythmic drugs for 3 months after their ablation.
Phase:
Phase 3
Details
Lead Sponsor:
Vanderbilt University Medical Center
Treatments:
Amiodarone
Anti-Arrhythmia Agents
Sotalol